Enanta Pharmaceuticals Inc (FRA:9EP)
€ 11.4 +0.30 (+2.78%) Market Cap: 326.71 Mil Enterprise Value: 233.81 Mil PE Ratio: 0 PB Ratio: 3.23 GF Score: 58/100

Q1 2020 Enanta Pharmaceuticals Inc Earnings Call Transcript

Feb 06, 2020 / 09:30PM GMT
Release Date Price: €50.5 (-0.98%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Enanta Pharmaceuticals first quarter financial results conference call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to Ms. Carol Miceli, Director of Investor Relations. Please go ahead, ma'am.

Carol Miceli
Enanta Pharmaceuticals, Inc. - Director of IR

Thank you, Erica, and thanks for joining us this afternoon. The news release with our fiscal first quarter financial results was issued today and is available on our website. On the call today is Dr. Jay Luly, President and CEO; Paul Mellett, our Chief Financial Officer; and other members of Enanta's senior management team.

Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements, which may include our plans and expectations with respect to our research and development pipeline and financial projections, all of which involve certain assumptions and risks beyond our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot